Abstract | PURPOSE: MATERIALS AND METHODS: Billing codes were used to identify 149 patients who underwent onabotulinumtoxinA injection between 2012-2016 at our tertiary transitional urology clinic. Charts were then reviewed to identify patients with congenital spinal dysraphism. RESULTS: A total of 18 patients with the mean age of 20.76 (±3.03) years at the time of 1st onabotulinumtoxinA injection were identified. All patients had urinary incontinence. Urinary incontinence improved by injection of 200 or 300 U of onabotulinumtoxinA in 81.2% of patients and 63.6% of them became dry (p= 0.023). Mean glomerular filtration rate before and 13.3 (±9) months after treatment was 100.2 (±17.2) and 120.1 (±16.6) mL/min/1.73 m2 respectively (p= 0.41). Baseline hydronephrosis improved in 3 of 4 patients. Repeat urodynamic study after injection was done in 11 patients who did not clinically improve or who had loss of bladder compliance at baseline (29.3 Vs. 67.2 ml/cmH2O). Mean maximum cystometric capacity before and after injection was 310.1 and 380.2 mL (p= 0.045). Mean bladder compliance before and after treatment was 29.2 and 28.7 ml/cmH2O respectively (p= 0.48) in this high risk group. CONCLUSIONS:
|
Authors | Aaron Kaviani, Rashmi Pande, Timothy B Boone, Rose Khavari |
Journal | Urology practice
(Urol Pract)
Vol. 6
Issue 2
Pg. 112-116
(Mar 2019)
ISSN: 2352-0779 [Print] United States |
PMID | 30906822
(Publication Type: Journal Article)
|